Can a DNA test predict who will respond to cancer immunotherapy?
NCT ID NCT05515796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to see if the test could identify who would have a complete response, meaning no cancer remains after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (immunotherapy drug) combined with chemotherapy (CapeOx) and/or trastuzumab and radiotherapy
- What this could lead to
- If successful, this could lead to a way to predict which patients will benefit from immunotherapy before treatment, improving outcomes for gastrointestinal cancers.
- What could go wrong
- This is a Phase 2 trial with 189 participants, so results are still early. The prediction model may not prove accurate enough for widespread use, and immunotherapy can cause serious immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY EFFECT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Army Medical Center
Chongqing, Other (Non U.s.), 400000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can diet and vitamin c supercharge rectal cancer treatment?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can we predict chemo brain before it happens?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?